Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer.

genitourinary oncology patient-reported outcomes prostate cancer radionuclide therapy radiopharmaceuticals

Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
06 2023
Historique:
received: 11 10 2022
revised: 20 12 2022
medline: 5 6 2023
pubmed: 13 1 2023
entrez: 12 1 2023
Statut: ppublish

Résumé

The field of radionuclide therapy (RNT) for prostate cancer (PC) is growing rapidly, with recent Food and Drug Administration approval of the first

Identifiants

pubmed: 36635088
pii: jnumed.122.264946
doi: 10.2967/jnumed.122.264946
pmc: PMC10241017
doi:

Substances chimiques

Radioisotopes 0

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

869-872

Subventions

Organisme : NCI NIH HHS
ID : P50 CA211015
Pays : United States

Informations de copyright

© 2023 by the Society of Nuclear Medicine and Molecular Imaging.

Références

N Engl J Med. 2013 Jul 18;369(3):213-23
pubmed: 23863050
Oncotarget. 2017 Jan 10;8(2):3581-3590
pubmed: 27683041
N Engl J Med. 2021 Sep 16;385(12):1091-1103
pubmed: 34161051
J Clin Oncol. 2016 Feb 20;34(6):557-65
pubmed: 26644527
Lancet. 2021 Feb 27;397(10276):797-804
pubmed: 33581798
J Nucl Med. 2021 Oct;62(10):1440-1446
pubmed: 34016732
Cancer. 2020 Apr 1;126(7):1550-1558
pubmed: 31914209
Health Qual Life Outcomes. 2003 Dec 16;1:79
pubmed: 14678568
Health Qual Life Outcomes. 2006 Oct 11;4:79
pubmed: 17034633
Urology. 1997 Dec;50(6):920-8
pubmed: 9426724
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Lancet Oncol. 2006 Nov;7(11):903-9
pubmed: 17081915
JAMA. 2017 Jul 11;318(2):197-198
pubmed: 28586821

Auteurs

Lisa M Gudenkauf (LM)

Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida; lisa.gudenkauf@moffitt.org.

Melody N Chavez (MN)

Participant Research, Interventions, and Measurements Core, Moffitt Cancer Center, Tampa, Florida.

Melinda Leigh Maconi (ML)

Participant Research, Interventions, and Measurements Core, Moffitt Cancer Center, Tampa, Florida.

Carley Geiss (C)

Participant Research, Interventions, and Measurements Core, Moffitt Cancer Center, Tampa, Florida.

Ameen Seyedroudbari (A)

Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.

Pan Thin (P)

Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.

Aasha I Hoogland (AI)

Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida.

Kathleen Nguyen (K)

Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.

Vishnu Murthy (V)

Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.

Wesley R Armstrong (WR)

Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.

Khaled Komrokji (K)

Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida.

Laura B Oswald (LB)

Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida.

Heather S L Jim (HSL)

Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida.

Ghassan El-Haddad (G)

Department of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, Florida.

Wolfgang P Fendler (WP)

Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium-University Hospital Essen, Essen, Germany.

Ken Herrmann (K)

Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium-University Hospital Essen, Essen, Germany.

David Cella (D)

Departments of Medical Social Sciences and Psychiatry and Behavioral Sciences, and Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Johannes Czernin (J)

Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.

Michael S Hofman (MS)

Prostate Cancer Theranostics and Imaging Centre of Excellence, Cancer Imaging, Peter MacCallum Centre, Melbourne, Victoria, Australia, and MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.

Adam P Dicker (AP)

Department of Pharmacology and Experimental Therapeutics, Sidney Kimmel Cancer, Thomas Jefferson University, Woodbury, New Jersey; and.

Jeremie Calais (J)

Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.

Scott T Tagawa (ST)

Department of Urology, Weill Cornell Medical College, New York, New York.

Brian D Gonzalez (BD)

Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH